PTCT PTC Therapeutics, Inc. Stock Quote

PTCT [NASD]

Index	-	P/E	-	EPS (ttm)	-7.38	Insider Own	0.70%	Shs Outstand	71.22M	Perf Week	9.31%
Market Cap	2.99B	Forward P/E	-	EPS next Y	-3.80	Insider Trans	-10.82%	Shs Float	69.15M	Perf Month	61.13%
Income	-522.00M	PEG	-	EPS next Q	-1.24	Inst Own	-	Short Float	8.13%	Perf Quarter	5.62%
Sales	569.40M	P/S	5.25	EPS this Y	-12.00%	Inst Trans	-1.22%	Short Ratio	7.10	Perf Half Y	9.92%
Book/sh	-1.27	P/B	-	EPS next Y	29.40%	ROA	-26.80%	Target Price	47.56	Perf Year	1.60%
Cash/sh	8.61	P/C	5.09	EPS next 5Y	-9.51%	ROE	-983.20%	52W Range	25.01 - 45.80	Perf YTD	9.92%
Dividend	-	P/FCF	-	EPS past 5Y	-12.20%	ROI	-31.90%	52W High	-6.31%	Beta	0.63
Dividend %	-	Quick Ratio	1.60	Sales past 5Y	45.50%	Gross Margin	94.10%	52W Low	71.57%	ATR	2.18
Employees	1252	Current Ratio	1.60	Sales Q/Q	26.10%	Oper. Margin	-63.70%	RSI (14)	73.62	Volatility	4.38% 6.52%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	2.90%	Profit Margin	-91.70%	Rel Volume	1.19	Prev Close	43.78
Shortable	Yes	LT Debt/Eq	-	Earnings	May 03 AMC	Payout	-	Avg Volume	791.71K	Price	42.91
Recom	2.50	SMA20	28.72%	SMA50	29.56%	SMA200	14.43%	Volume	945,663	Change	-1.99%

Apr-04-22

Resumed

Cantor Fitzgerald

Overweight

$64 → $63

Oct-18-21

Downgrade

BofA Securities

Neutral → Underperform

$38

Apr-26-21

Resumed

Credit Suisse

Neutral

$54

Mar-29-21

Upgrade

RBC Capital Mkts

Underperform → Sector Perform

$47

Feb-12-21

Downgrade

BofA Securities

Buy → Neutral

Jan-05-21

Upgrade

Citigroup

Neutral → Buy

$67 → $85

Nov-30-20

Downgrade

RBC Capital Mkts

Sector Perform → Underperform

$45

Oct-30-20

Downgrade

Citigroup

Buy → Neutral

Oct-28-20

Initiated

UBS

Neutral

$55

Oct-07-20

Upgrade

JP Morgan

Neutral → Overweight

$71

Aug-25-20

Initiated

Raymond James

Outperform

$63

Apr-09-20

Upgrade

Citigroup

Neutral → Buy

$71 → $67

Feb-20-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

Feb-20-20

Downgrade

Citigroup

Buy → Neutral

$55 → $71

Nov-12-19

Initiated

SunTrust

Buy

$78

May-13-19

Upgrade

BofA/Merrill

Neutral → Buy

$43 → $49

Apr-11-19

Initiated

Bernstein

Outperform

$48

Oct-03-18

Upgrade

BofA/Merrill

Underperform → Neutral

Oct-01-18

Initiated

Cantor Fitzgerald

Overweight

$66

Jul-19-18

Initiated

Credit Suisse

Outperform

$49

Jun-23-22 04:11PM	PTC Stock Has Gained 41% This Week Alone, And It's Still Sprinting Investor's Business Daily +11.35%
Jun-20-22 04:00PM	PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy PR Newswire
Jun-09-22 08:00AM	Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors PR Newswire
Jun-06-22 08:00AM	PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference PR Newswire -6.03%
Jun-03-22 08:00AM	Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study PR Newswire +5.52%
Jun-01-22 09:49AM	PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 20% Above Their Intrinsic Value Estimate Simply Wall St.
May-31-22 01:00AM	FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old PR Newswire
May-24-22 03:13PM	Raymond James Says PTC Therapeutics' CHMP Backing Is 'Under Exceptional Circumstances' What's Next Benzinga
May-20-22 01:50PM	Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder Benzinga
08:08AM	PTC Therapeutics Receives Positive CHMP Opinion for Upstaza for the Treatment of AADC Deficiency PR Newswire
May-03-22 05:45PM	PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results PR Newswire
Apr-29-22 04:30PM	PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
Apr-26-22 03:01PM	Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know Zacks -6.65%
Apr-19-22 08:00AM	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results PR Newswire
Apr-14-22 08:30AM	PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program PR Newswire
Apr-13-22 09:29AM	Investors in Therapeutics (NASDAQ:PTCT) have made a impressive return of 291% over the past five years Simply Wall St.
Apr-08-22 04:23PM	PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Apr-04-22 07:32AM	PTC Therapeutics (PTCT) Soars 11.1%: Is Further Upside Left in the Stock? Zacks
Mar-30-22 04:00PM	PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease PR Newswire
Mar-14-22 05:18AM	United Therapeutics (UTHR) Moves 3.1% Higher: Will This Strength Last? Zacks
Mar-11-22 08:00AM	PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference PR Newswire
Feb-23-22 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire -7.33%
Feb-22-22 05:25PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM	PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results PR Newswire
Feb-18-22 08:46AM	Is a Surprise Coming for PTC Therapeutics (PTCT) This Earnings Season? Zacks
Feb-15-22 03:01PM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Feb-08-22 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results PR Newswire
Jan-25-22 01:00AM	FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy PR Newswire
Jan-18-22 08:00AM	PTC Therapeutics Announces Launch of 8th Annual STRIVE Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community PR Newswire -5.28%
Jan-13-22 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08:00AM	PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program PR Newswire
04:16AM	Analysts' Revenue Estimates For PTC Therapeutics, Inc. (NASDAQ:PTCT) Are Surging Higher Simply Wall St.
Jan-11-22 08:19AM	Strength Seen in PTC Therapeutics (PTCT): Can Its 5.1% Jump Turn into More Strength? Zacks
Jan-10-22 07:00AM	PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference PR Newswire +5.07%
Jan-04-22 08:00AM	Waylivra Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil PR Newswire
Jan-03-22 08:00AM	PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference PR Newswire +6.90%
Dec-23-21 07:39AM	PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 37% Below Their Intrinsic Value Estimate Simply Wall St.
Dec-20-21 08:00AM	Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform PR Newswire
Dec-15-21 03:38PM	PTC Therapeutics, Inc. (PTCT): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-09-21 07:39AM	ICOTF: Targeting Stem Cells for Muscular Dystrophy Treatment Zacks Small Cap Research -5.91%
Dec-06-21 09:13AM	Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery PR Newswire
Dec-02-21 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-16-21 08:00AM	PTC Therapeutics to Participate at Upcoming Virtual Investor Conference PR Newswire
Nov-08-21 12:51PM	Is Therapeutics (NASDAQ:PTCT) Weighed On By Its Debt Load? Simply Wall St.
Oct-29-21 12:31AM	PTC Therapeutics Inc (PTCT) Q3 2021 Earnings Call Transcript Motley Fool
Oct-28-21 05:15PM	PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:00PM	PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results PR Newswire
Oct-26-21 08:00AM	PTC Therapeutics to Participate at Upcoming Virtual Investor Conference PR Newswire
Oct-25-21 09:56PM	Where Do Hedge Funds Stand On PTC Therapeutics, Inc. (PTCT)? Insider Monkey
08:00AM	PTC Announces Expansion of Translarna Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil PR Newswire
Oct-21-21 03:03PM	Earnings Preview: PTC Therapeutics (PTCT) Q3 Earnings Expected to Decline Zacks
Oct-14-21 08:58AM	PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results PR Newswire
08:30AM	PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility PR Newswire
Oct-11-21 08:00AM	Tegsedi® Receives Innovative Drug Category Pricing in Brazil PR Newswire
Oct-06-21 08:16PM	The Recent Pullback in These 2 Stocks Is a Buying Opportunity, Say Analysts TipRanks
Sep-29-21 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
12:30PM	PTC Therapeutics' Rare Genetic Disease Gene Therapy Shows Durable Improvement Even At 5 Years Benzinga
08:00AM	Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy PR Newswire
Sep-20-21 04:30PM	PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program PR Newswire
08:30AM	STRIDE Data Show Translarna Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy PR Newswire
Sep-13-21 08:00AM	Aadi Bioscience Appoints Emma Reeve to its Board of Directors GlobeNewswire
Sep-07-21 08:00AM	PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community PR Newswire
Aug-27-21 08:00AM	PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PR Newswire +5.25%
Aug-24-21 07:06AM	PTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic Disorder Benzinga
Aug-23-21 04:30PM	PTC Therapeutics Announces Waylivra Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome PR Newswire
09:00AM	Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency PR Newswire
Aug-20-21 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Aug-10-21 04:34AM	Investing in Therapeutics (NASDAQ:PTCT) five years ago would have delivered you a 385% gain Simply Wall St.
Jul-29-21 04:00PM	PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results PR Newswire
Jul-28-21 05:00PM	Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi PR Newswire
Jul-22-21 03:03PM	PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-19-21 12:58PM	Do Hedge Funds Love PTC Therapeutics, Inc. (PTCT)? Insider Monkey
Jul-15-21 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results PR Newswire
Jun-24-21 08:00AM	Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone PR Newswire
Jun-23-21 08:00AM	Evrysdi Approved in Japan for the Treatment of Spinal Muscular Atrophy PR Newswire
Jun-15-21 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jun-11-21 07:10AM	A Look At The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT) Simply Wall St.
01:00AM	Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi in RAINBOWFISH PR Newswire
Jun-09-21 08:00AM	Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors PR Newswire
May-27-21 10:23AM	PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU Zacks
May-26-21 08:00AM	PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia PR Newswire
May-19-21 08:00AM	PTC Therapeutics to Participate at Upcoming Virtual Investor Conference PR Newswire
May-17-21 08:00AM	New Data Shows Devastating Impact of AADC Deficiency on Caregivers PR Newswire
May-04-21 05:25PM	PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates Zacks -5.64%
04:01PM	PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results PR Newswire
02:30PM	PTC Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Apr-30-21 06:29AM	PTC Therapeutics (PTCT) Enters Oversold Territory Zacks
Apr-27-21 08:00AM	PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PR Newswire
Apr-24-21 05:08PM	Is PTCT Stock A Buy or Sell? Insider Monkey
Apr-20-21 08:00AM	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results PR Newswire
Apr-19-21 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Apr-15-21 01:00AM	Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi PR Newswire
Apr-14-21 08:00AM	PTC Therapeutics Launches the PTC Pinpoint Direct Program for Patient-Initiated Genetic Testing PR Newswire
Apr-12-21 07:35AM	Is Therapeutics (NASDAQ:PTCT) Using Debt In A Risky Way? Simply Wall St.
Apr-07-21 09:30AM	PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award PR Newswire
08:50AM	PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar PR Newswire
Apr-01-21 08:00AM	PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi PR Newswire
Mar-30-21 07:05AM	PTC Therapeutics-Roche's Evrysdi Approved In Europe For Muscular Atrophy Benzinga
01:00AM	PTC Therapeutics Announces the European Approval of Evrysdi for the Treatment of Spinal Muscular Atrophy PR Newswire

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Svoronos Dawn	Director	Jun 09	Sale	27.20	738	20,074	29,017	Jun 10 04:06 PM
Peltz Stuart Walter	CHIEF EXECUTIVE OFFICER	Jun 07	Sale	26.83	407	10,919	38,239	Jun 09 04:03 PM
Klein Matthew B.	CHIEF OPERATING OFFICER	Apr 19	Sale	42.52	897	38,136	56,564	Apr 21 04:03 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Apr 19	Sale	42.52	822	34,947	49,772	Apr 21 04:02 PM
Peltz Stuart Walter	CHIEF EXECUTIVE OFFICER	Apr 14	Sale	45.28	82	3,713	38,646	Apr 15 04:04 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Apr 13	Option Exercise	11.23	2,276	25,559	63,386	Apr 15 04:02 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Apr 13	Sale	45.17	2,276	102,811	61,110	Apr 15 04:02 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Apr 05	Option Exercise	11.23	5	56	61,115	Apr 07 04:03 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Apr 05	Sale	45.00	5	225	61,110	Apr 07 04:03 PM
Hill Emily Luisa	CHIEF FINANCIAL OFFICER	Mar 31	Sale	37.78	7,910	298,824	29,259	Apr 01 04:20 PM
Boulding Mark Elliott	Exec. VP and CLO	Feb 10	Option Exercise	17.15	17,935	307,537	76,763	Feb 11 04:11 PM
Boulding Mark Elliott	Exec. VP and CLO	Feb 10	Sale	45.03	17,935	807,559	61,110	Feb 11 04:11 PM
Utter Christine Marie	SVP, Finance & CAO	Feb 02	Sale	40.38	707	28,549	25,405	Feb 03 04:59 PM
Boulding Mark Elliott	Exec. VP and CLO	Feb 01	Sale	40.00	779	31,162	61,110	Feb 03 04:57 PM
Hill Emily Luisa	Chief Financial Officer	Feb 01	Sale	40.00	553	22,121	37,169	Feb 03 04:58 PM
Pauwels Eric	Chief Business Officer	Feb 01	Sale	40.00	367	14,681	50,594	Feb 03 04:58 PM
Peltz Stuart Walter	Chief Executive Officer	Feb 01	Sale	40.00	282	11,281	38,728	Feb 03 04:58 PM
Peltz Stuart Walter	Chief Executive Officer	Feb 01	Sale	40.00	1,961	78,444	120,485	Feb 03 04:58 PM
Utter Christine Marie	SVP, Finance & CAO	Feb 01	Sale	40.00	313	12,521	26,112	Feb 03 04:59 PM
Almstead Neil Gregory	Chief Technical Ops Officer	Feb 01	Sale	40.00	27	1,080	2,420	Feb 03 04:57 PM
Almstead Neil Gregory	Chief Technical Ops Officer	Feb 01	Sale	40.00	605	24,201	48,853	Feb 03 04:57 PM
Hill Emily Luisa	Chief Financial Officer	Jan 25	Sale	39.31	211	8,295	37,722	Jan 27 04:01 PM
Pauwels Eric	Chief Business Officer	Jan 25	Sale	39.31	359	14,114	50,961	Jan 27 04:02 PM
Peltz Stuart Walter	Chief Executive Officer	Jan 25	Sale	39.31	330	12,974	39,010	Jan 27 04:02 PM
Almstead Neil Gregory	Chief Technical Ops Officer	Jan 25	Sale	39.31	43	1,691	2,447	Jan 27 04:01 PM
Utter Christine Marie	SVP, Finance & CAO	Jan 18	Option Exercise	18.01	10,000	180,100	36,425	Jan 20 04:50 PM
Utter Christine Marie	SVP, Finance & CAO	Jan 18	Sale	43.94	11,428	502,118	26,425	Jan 20 04:50 PM
Almstead Neil Gregory	Chief Technical Ops Officer	Jan 07	Sale	38.52	45	1,734	1,710	Jan 11 04:20 PM
Almstead Neil Gregory	Chief Technical Ops Officer	Jan 07	Sale	38.52	756	29,125	35,058	Jan 11 04:20 PM
Utter Christine Marie	SVP, Finance & CAO	Jan 07	Sale	38.52	747	28,778	16,253	Jan 11 04:21 PM
Boulding Mark Elliott	Exec. VP and CLO	Jan 07	Sale	38.52	885	34,095	47,489	Jan 11 04:19 PM
Klein Matthew B.	Chief Operating Officer	Jan 07	Sale	38.52	775	29,857	16,461	Jan 11 04:18 PM
Hill Emily Luisa	Chief Financial Officer	Jan 07	Sale	38.52	800	30,820	22,333	Jan 11 04:18 PM
Pauwels Eric	Chief Business Officer	Jan 07	Sale	38.52	866	33,363	34,520	Jan 11 04:17 PM
Peltz Stuart Walter	Chief Executive Officer	Jan 07	Sale	38.52	294	11,326	22,540	Jan 11 04:16 PM
Peltz Stuart Walter	Chief Executive Officer	Jan 07	Sale	38.52	1,869	72,003	78,446	Jan 11 04:16 PM
Svoronos Dawn	Director	Jan 07	Sale	38.52	510	19,648	26,555	Jan 11 04:14 PM
Hill Emily Luisa	Chief Financial Officer	Jan 04	Sale	41.16	173	7,121	23,133	Jan 06 04:10 PM
Almstead Neil Gregory	Chief Technical Ops Officer	Jan 04	Sale	41.16	64	2,634	1,755	Jan 06 04:10 PM
Peltz Stuart Walter	Chief Executive Officer	Jan 04	Sale	41.16	378	15,559	22,834	Jan 06 04:08 PM
Pauwels Eric	Chief Business Officer	Jan 04	Sale	41.16	806	33,177	35,386	Jan 06 04:09 PM
Boulding Mark Elliott	Exec. VP and CLO	Sep 02	Option Exercise	18.01	3,363	60,568	51,737	Sep 03 04:06 PM
Boulding Mark Elliott	Exec. VP and CLO	Sep 02	Sale	45.01	3,363	151,375	48,374	Sep 03 04:06 PM
Okey Stephanie	Director	Aug 13	Sale	40.06	1,650	66,094	963	Aug 17 04:04 PM
Boulding Mark Elliott	Exec. VP and CLO	Jul 09	Option Exercise	18.01	1,429	25,736	48,922	Jul 12 04:26 PM
Boulding Mark Elliott	Exec. VP and CLO	Jul 09	Sale	45.00	1,429	64,306	48,374	Jul 12 04:26 PM
Boulding Mark Elliott	Exec. VP and CLO	Jul 08	Option Exercise	16.27	7,805	127,008	50,174	Jul 12 04:26 PM
Boulding Mark Elliott	Exec. VP and CLO	Jul 08	Sale	45.22	7,805	352,968	48,374	Jul 12 04:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience